These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 27479819)

  • 1. Identification of a new potential mechanism responsible for severe bleeding in myeloma: immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant.
    Martínez-Martínez I; González-Porras JR; Cebeira MJ; de Arriba F; Espín S; Bohdan N; Corrales FJ; Corral J; Vicente V
    Haematologica; 2016 Oct; 101(10):e423-e426. PubMed ID: 27479819
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.
    Chen Y; Lin L; Agyekum I; Zhang X; St Ange K; Yu Y; Zhang F; Liu J; Amster IJ; Linhardt RJ
    J Pharm Sci; 2017 Apr; 106(4):973-981. PubMed ID: 28007564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticoagulant activation of antithrombin by heparin.
    Jin L; Abrahams JP; Skinner R; Petitou M; Pike RN; Carrell RW
    Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14683-8. PubMed ID: 9405673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.
    Lormeau JC; Herault JP; Herbert JM
    Thromb Haemost; 1996 Jul; 76(1):5-8. PubMed ID: 8819242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site.
    Cesaretti M; Luppi E; Maccari F; Volpi N
    Glycobiology; 2004 Dec; 14(12):1275-84. PubMed ID: 15253929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of different anticoagulant activities.
    Jones GR; Hashim R; Power DM
    Biochim Biophys Acta; 1986 Aug; 883(1):69-76. PubMed ID: 3730427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human antithrombin III-derived heparin-binding peptide, a novel heparin antagonist.
    Onoue S; Nemoto Y; Harada S; Yajima T; Kashimoto K
    Life Sci; 2003 Oct; 73(22):2793-806. PubMed ID: 14511765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites.
    Desai UR; Petitou M; Björk I; Olson ST
    Biochemistry; 1998 Sep; 37(37):13033-41. PubMed ID: 9737884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanism for heparin-induced potentiation of antithrombin III.
    van Boeckel CA; Grootenhuis PD; Visser A
    Nat Struct Biol; 1994 Jul; 1(7):423-5. PubMed ID: 7664058
    [No Abstract]   [Full Text] [Related]  

  • 11. Energetics of hydrogen bond switch, residue burial and cavity analysis reveals molecular basis of improved heparin binding to antithrombin.
    Singh P; Singh K; Jairajpuri MA
    J Biomol Struct Dyn; 2011 Oct; 29(2):339-50. PubMed ID: 21875153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.
    Pimenta DC; Nantes IL; de Souza ES; Le Bonniec B; Ito AS; Tersariol IL; Oliveira V; Juliano MA; Juliano L
    Biochem J; 2002 Sep; 366(Pt 2):435-46. PubMed ID: 12000310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of thrombin inactivation by immobilized heparin.
    Byun Y; Jacobs HA; Kim SW
    J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
    Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site.
    Skinner R; Abrahams JP; Whisstock JC; Lesk AM; Carrell RW; Wardell MR
    J Mol Biol; 1997 Feb; 266(3):601-9. PubMed ID: 9067613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy.
    Tyler-Cross R; Sobel M; Marques D; Harris RB
    Protein Sci; 1994 Apr; 3(4):620-7. PubMed ID: 8003980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.